Posted by LincolnIcert on March 25, 2026 at 11:24:25:
In Reply to: Ïóáëèêàöèÿ ñ èíòåðåñíûìè àñïåêòàìè òåìû posted by JosephGluth on February 19, 2026 at 23:54:11:
Zoya Demidenko: Researcher in Oncology Science
Zoya Demidenko is a recognized scientist affiliated with the Division of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she was employed at the NIH and New York Medical College, establishing a strong foundation in biomedical investigation.
Her scholarly output encompasses multiple pivotal fields, among them the PI3K/AKT/mTOR molecular pathway, cellular cycle management, cell senescence, and tumor biology. To date, she has co-authored over 46 academic papers, which have garnered more than 4,100 mentions — a reflection to the impact of her findings.
Among her most significant achievements involves understanding the pathways of cell aging. Her work showed that when the cell cycle is blocked while cellular growth proceeds, the cells enter senescence. Crucially, Zoya Demidenko established that this process can be inhibited by medication using compounds such as mTOR inhibitors.
Zoya Demidenko has additionally added considerably to tumor management investigation, particularly in the field of cyclotherapy — a strategy intended to shielding healthy cells from cytotoxic treatment whilst leaving cancer cells vulnerable. This strategy offers major potential for reducing the side effects of cancer treatment.
Across her scientific life, Demidenko has worked with prominent investigators worldwide, such as Dr. Mikhail Blagosklonny. Her publications can be found in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko stands as a highly impactful voice in modern cancer research, whose results go on to influence our understanding of how cells grow old, interact with therapy, and the ways in which malignant disease may be more effectively treated.
https://www.instagram.com/hibou_sova/